GemVax Completes 7 Billion Won Premium Convertible Bond Issuance: Secures R&D Funding While Dilution Risk Persists

GemVax has completed the issuance of the 16th series of unsecured private convertible bonds worth 7 billion KRW, with payment date on June 1, 2026.
The conversion price is 18,659 KRW, a 12% premium over the closing price on the subscription date. Upon conversion, 375,154 shares will be issued, representing a 0.84% dilution.
The proceeds will be used for R&D expenses for clinical trials including Progressive Supranuclear Palsy (PSP).
Total potential dilution including previously issued convertible bonds is 5.03%.
[AI Summary]This completion of the convertible bond issuance is in line with previously disclosed plans, with funds allocated to R&D potentially enhancing long-term enterprise value, but the dilution risk remains.